U.S. Markets closed

Seattle Genetics, Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.51-0.09 (-0.14%)
At close: 4:00PM EDT

66.51 0.00 (0.00%)
After hours: 4:19PM EDT

People also watch
  • Are we up because of the abstracts at ASCO?
  • ASG-22: Three (3) complete responses so far at the high dose range. Ricardo is impressed.
  • Clay, the CEO, just unloaded another chunk. Must be nice. I'd buy a Rolex Cosmograph for all my friends with the proceeds and then maybe a Maserati
  • Finally some common sense clarity on the IMMU expedition. Wish them well and hope that the door doesn not slam on they backside on the way out. Let's see how VenBios finances IMMU 132 trials now and how experienced they are at convincing the FDA for an early conditional approval based on the very limited PII data that they have on hand and are afraid to present at ASCO for the second time. Only beef I have with SGEN is that they did not take profit on the original investment while they had it. Maybe they could not by covenant. I doubt that they get a better deal from a new partner when 30% OF PIII's fail in spite of good PII results.
  • I sold some in my Roth IRA at 69 and bought it back under 60. It's up a few bucks. Hope it hits
    65+ this week
  • Why the big drop????
  • so when do we stop bleeding?
  • It is clear from the current neutral insider ownership of 0.90% that SGEN could yield both a pullback or an uptick. The scenarios are quite interesting at current levels. if you guys have questions you should ask a.awesomestocks. They often respond to my emails which is helpful.
  • Two things that might be easy to miss in the just-released 1Q report (in which revenues beat and earnings/losses were in-line):

    1. The last sentence in this paragraph: "Royalty revenues of $17.0 million, compared to $32.3 million in the first quarter of 2016. Royalty revenues are primarily driven by international sales of ADCETRIS by Takeda. Royalty revenues in the first quarter of 2016 included a $20.0 million sales milestone payment from Takeda."

    2. And this, meaning we'll see the revenue in Q2 results: "ADC Collaborations: In April 2017, Seattle Genetics generated a milestone under its ongoing ADC collaboration with AbbVie triggered by AbbVie’s exercise of an exclusive option to Seattle Genetics’ ADC technology for a specific target antigen."
  • We look to be setting up for a nice move...it's been a while but we're about due to make a new high...and, as the previous poster opines, going right to $75...In actuality, I think we're ready to get over that hurdle.

    The screwing around with IMMU has been "fun" to watch and it'll be interesting to see if SGEN and IMMU can make something work...though I think the other side and venBio are trying to wrangle something else.
  • Smart post Yahoo Reader. You hit the nail on the head about trading this stock.
  • Clay's response on the $IMMU deal.

    "Yeah. Sure. The IMMU deal, right now it's a legal issue and so we're not providing any specific updates. As you know the facts are that there was a temporary restraining order or TRO, and the fact is that there is a trial listed in late June. But please keep in mind that when we think about it IMMU-132, this was something that we thought fit in and we thought would be nice to have with the rest of our very extensive pipeline. But it is certainly not something that is needed. We have many programs that we're focused on and pushing forward hard on, but otherwise to answer to your question, it's a legal issue and it's not appropriate to make comment."
  • Revenues were good. I don't see any after-hours pricing.
  • When this #$%$ breaks $70, it's going right to 75
  • Nice pop today. 🤑
  • The judge ordered 30 day delay in the IMMU saga was over yesterday but not a peep. Wish they would just walk away from this deal. $300 million upfront for a PII drug that may garner conditional FDA approval is a pretty good deal for the cash strapped IMMU shareholder and a price that no one else is apparently willing to even match in spite of what I now two additional months of going shopping. I think the evidence supports SGEN reconsidering the deal and scaling back at least the upfront payment if not completely walk away and let VenBio deal with the fallout.
  • AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $50.6 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Nice to see with the AACR abstracts that our collaboration with Unum therapeutics and their antibody coupled T cell therapy has been moving forward. I'm drawing a blank on one of the abstracts and it's intended target, but the second abstract appears to have NSCLC and hepatocellular carcinoma as the target malignancies.
    Quite a bit as well on SGEN's own immuno-onc agents being developed including SEA-CD40 and 2FF. AACR is for the scientists as everything is taken down to the molelecular level so It's rare to see this conference produce stock movement but from a company perspective SGEN had a lot to offer in this meeting..It's kind of an early peek into the future beyond just Adcetris.
  • Anyone have any insight as to when the court will decide whether to allow the deal with IMMU to proceed?
  • Why the big drop in after hours?